Background: PTK2 (focal adhesion kinase) is implicated in cancer progression and metastasis. This study was aimed to comprehensively analyze the PTK2 expression patterns, protein interactions, and its correlation with immune infiltration in bladder cancer to elucidate its clinical relevance.

Methods: Public databases including The Cancer Genome Atlas, UALCAN, STRING, and Tumor Immune Estimation Resource were evaluated. Differential PTK2 mRNA expression in bladder tumors versus normal tissues was evaluated. PTK2 correlations with cancer stage, gender, immune infiltrates, and integrin β1 expression were examined. Protein-protein interaction networks were generated using STRING.

Results: PTK2 was significantly overexpressed in bladder cancer, especially in higher-stage tumors. PTK2 positively correlated with B cells and macrophages but negatively correlated with CD4+ T cells and dendritic cells. Increased CD8+ T cell infiltration is associated with a better prognosis. Protein network analysis showed that PTK2 interacts with several proteins including INTB1, INTB3, PTEN, PI3K, CRK, PXN, VCL, BCAR1, GRB2, and SRC. Gene expression analysis revealed a positive correlation between PTK2 and INTB1 gens.

Conclusions: Bioinformatics analyses implicate PTK2 overexpression in bladder cancer progression and associations with immunosuppressive microenvironments. Findings suggest PTK2 may be a potential prognostic biomarker and therapeutic target warranting further investigation. More experimental validation is needed to confirm computational perspectives.

Keywords: PTK2; INTB1; Bladder Cancer

References

1. Hu X., et al. “Advances in diagnosis and therapy for bladder cancer”. Cancers13 (2022): 3181.
2. Lobo N., et al. “Epidemiology, screening, and prevention of bladder cancer”. European Urology Oncology (2022).
3. Mungan NA., et al. “Gender differences in stage-adjusted bladder cancer survival”. Urology6 (2000): 876-880.
4. Abdollah F., et al. “Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis”. Cancer Epidemiology3 (2013): 219-225.
5. Shafiekhani M., et al. “Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review”. Therapeutic Advances in Urology 13 (2021): 17562872211046794.
6. Chamie K., et al. “Recurrence of high‐risk bladder cancer: a population‐based analysis”. Cancer17 (2013): 3219-3227.
7. Tomlinson D., et al. “FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer”. The Journal of Pathology1 (2007): 91-98.
8. Ciccarese C., et al. “Tp53 and its potential therapeutic role as a target in bladder cancer”. Expert Opinion on Therapeutic Targets4 (2017): 401-414.
9. Zhao J., et al. “Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1”. Urologic Oncology: Seminars and Original Investigations (2018).
10. Sathe A and Nawroth R. “Targeting the PI3K/AKT/mTOR pathway in bladder cancer”. Urothelial Carcinoma: Methods and Protocols (2018): 335-350.
11. Fan Z., et al. “PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling”. Cancer Letters 450 (2019): 132-143.
12. Zhang L., et al. “MiR-520d-5p functions as a tumor-suppressor gene in cervical cancer through targeting PTK2”. Life Sciences 254 (2020): 117558.
13. Luo P., et al. “PTK2 promotes uveal melanoma metastasis by activating epithelial‐to‐mesenchymal transition”. MedComm-Oncology3 (2023): e44.
14. Xu Z., et al. “Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment”. Molecular Therapy (2022).
15. Arora S., et al. “Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers”. Seminars in Cancer Biology (2022).
16. Ozmadenci D., et al. “Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis”. Proceedings of the National Academy of Sciences17 (2023): e2117065119.
17. Ghasemi H., et al. “Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection”. Annals of the New York Academy of Sciences1 (2020): 48-61.
18. Wu K., et al. “To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis”. Journal of Advanced Research 20 (2019): 43-50.
19. Chandrashekar DS., et al. “UALCAN: An update to the integrated cancer data analysis platform”. Neoplasia 25 (2022): 18-27.
20. Chandrashekar DS., et al. “UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses”. Neoplasia8 (2017): 649-658.
21. Li T. “TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells”. Cancer Research 77 (2017): e108-e110.
22. Li B., et al. “Comprehensive analyses of tumor immunity: implications for cancer immunotherapy”. Genome biology1 (2016): 1-16.
23. Li T., et al. “TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells”. Cancer Research21 (2017): e108-e10.
24. von Mering C., et al. “STRING 7—recent developments in the integration and prediction of protein interactions”. Nucleic Acids Research 35 (2006): D358-D62.
25. Kamat AM., et al. “Bladder cancer”. The Lancet10061 (2016): 2796-2810.
26. Society AC. “Cancer facts and figures 2017”. American Cancer Society Atlanta (2013).
27. Kaufman DS., et al. “Bladder cancer”. The Lancet9685 (2009): 239-249.
28. Tang C., et al. “Functional nanomedicines for targeted therapy of bladder cancer”. Frontiers in Pharmacology 12 (2021): 778973.
29. Xu ZQ., et al. “Circular RNA hsa_circ_0003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells”. Journal of Cellular Biochemistry4 (2018): 331725.
30. McLean GW., et al. “The role of focal adhesion kinase in cancer—a new therapeutic opportunity”. Nature Reviews Cancer7 (2005): 505-515.
31. Maung K., et al. “Requirement for focal adhesion kinase in tumor cell adhesion”. Oncogene48 (1999): 6824-6828.
32. Sulzmaier FJ., et al. “FAK in cancer: mechanistic findings and clinical applications”. Nature Reviews Cancer9 (2014): 598-610.
33. Frisch SM., et al. “Control of adhesion-dependent cell survival by focal adhesion kinase”. Journal of Cell Biology 3 (1996): 793-799.
34. Reddig PJ and Juliano RL. “Clinging to life: cell to matrix adhesion and cell survival”. Cancer Metastasis Review 3 (2005): 425-439.
35. Lee BY., et al. “FAK signaling in human cancer as a target for therapeutics”. Pharmacology and Therapeutics 146 (2015): 132-149.
36. Kong DB., et al. “Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin”. Oncology Targets Therapy 10 (2017): 1783-1792.
37. Kong D., et al. “Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway”. Experimental and Therapeutic Medicine5 (2015): 1725-1731.
38. Ghasemi H., et al. “Transitional cell carcinoma matrix stiffness regulates the osteopontin and YAP expression in recurrent patients”. Molecular Biology Reports5 (2021): 4253-4262.
39. Benzekry S., et al. “Design principles for cancer therapy guided by changes in complexity of protein-protein interaction networks”. Biology Direct1 (2015): 32.
40. Nabavizadeh SS., et al. “Attenuation of osteoarthritis progression through intra-articular injection of a combination of synovial membrane-derived MSCs (SMMSCs), platelet-rich plasma (PRP) and conditioned medium (secretome)”. Journal of Orthopaedic Surgery and Research 1 (2022): 1-12.
41. Khaled D., et al. “Salvage therapy for non-muscle-invasive bladder cancer: novel intravesical agents”. Urologic Clinics 1 (2020): 119-128.
42. Babjuk M., et al. “European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update”. European Urology5 (2019): 639-657.
43. Peng M., et al. “Novel Combination Therapies for the Treatment of Bladder Cancer”. Frontiers in Oncology 10 (2021).
44. Leek RD., et al. “Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma”. Cancer Research 20 (1996): 46259.
45. Hanada T., et al. “Prognostic value of tumorassociated macrophage count in human bladder cancer”. International Journal of Urology 7 (2000): 263-269.
46. Liu Z., et al. “Intratumoral TIGIT (+) CD8 (+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer”. Journal of Immunotherapy Cancer 2 (2020).
47. Zhu W., et al. “CD8+ CD39+ T cells mediate anti-tumor cytotoxicity in bladder cancer”. OncoTargets and Therapy (2021): 2149-2161.
48. Liakou CI., et al. “Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer”. Cancer Immunity 7 (2007): 10.
49. Oh DY., et al. “Intratumoral CD4 (+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer”. Cell 7 (2020): 1612-25.e13.
50. Zhou J., et al. “Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer”. Journal of Translational Medicine1 (2014): 304.
51. Shi H., et al. “A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with radical cystectomy for bladder cancer”. Translational Cancer Research 9 (2020): 5255-5267.

Citation

Citation: Hadi Ghasemi.,et al. “PTK2 mRNA Expression in Bladder Cancer: Insights from Multi-Dimensional Analysis and Gene Interaction Networks”.Acta Scientific Cancer Biology 8.2 (2024): 22-30.

Copyright

Copyright: © 2024 Hadi Ghasemi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.